High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints

被引：3

作者：

Jansen, Anouk M. E. ^{[1
,2
]}

ter Heine, Rob ^{[1
]}

Verweij, Paul E. ^{[2
,3
]}

Bruggemann, Roger J. M. ^{[1
,2
]}

机构：

[1] Radboud Univ Nijmegen, Radboud Inst Med Innovat, Dept Pharm, Med Ctr, Geert Grootepl Zuid 10,Postbox 9101, NL-6500 HB Nijmegen, Netherlands

[2] Radboud Univ Nijmegen, Canisius Wilhelmina Ziekenhuis Ctr Expertise Myco, Med Center, Nijmegen, Netherlands

[3] Radboud Univ Nijmegen, Radboud Inst Med Innovat, Dept Med Microbiol, Med Center, Nijmegen, Netherlands

来源：

CLINICAL PHARMACOKINETICS | 2023年 / 62卷 / 12期

关键词：

ASPERGILLUS;

D O I：

10.1007/s40262-023-01311-w

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Isavuconazole exposure-response relationships have been studied with a focus on total rather than unbound exposure, assuming a constant unbound fraction of 1%. We observed a median (range) unbound fraction of 1.59% (0.42-5.30%) in patients. This highly variable protein binding asks for re-evaluation of current pharmacokinetic and pharmacodynamic targets for isavuconazole.

引用

页码：1695 / 1699

页数：5